 | • レポートコード：D0-MOR-AP0512 • 出版社/出版日：Mordor Intelligence / 2020年4月20日 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：健康管理 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、遺伝子送達体の世界市場について調査・分析した資料で、遺伝子送達体の市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。 |
The gene delivery systems market studied was anticipated to grow with a CAGR of 7.3%, over the forecast period. The significant factor attributing to the market’s growth is the rising incidence & prevalence of chronic diseases and increasing technological advancement in drug delivery. The increasing ongoing research and development in the field of genomics across the globe also drive the gene delivery systems market. Chronic diseases in developing countries are responsible for more fatalities. Some of the leading chronic diseases in developed countries such as the United States are cardiovascular diseases, infectious diseases, cancer, diabetes, and others. As per the CDC (Centers for Disease Control and Prevention), six in ten adults in the United States have a chronic disease. As per the statistics, globally one in three adults has more than two or more chronic diseases, know as multiple chronic conditions. Gene delivery systems can help emmensly in imporving the human therapeutics used for the disease treatment. All these key factors are expected to boost the growth of gene delivery systems market over the forecast period.
Key Market Trends
Viral Gene Delivery Systems segment is Expected to Hold the Largest Share in the Gene Delivery Systems Market
– Dominat share is expected to be retained by the viral gene delivery systems owing to the attributes such as long-term expression, short term expression, and efficacy of therapeutic genes, and the rising advancement in technology over the last few years which has opened up many opportunities for growth in the healthcare industry. The increase in the prevalence of chronic diseases such as cancer and cardiovascular disorders is also aiding to the better market growth of gene delivery systems.
– The growing emphasis on governing and raising awareness about these treatments by governments in different countries has resulted in the rapid acceptance of these gene delivery systems worldwide. The rising support for R&D, along with the strong market position of major biopharmaceutical market players, has created a better entry passage for new market entrants.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to maintain its supremacy in the overall gene delivery systems market, throughout the forecast period. This is owing to factors such as the rising prevalence of chronic diseases in the region, technological advancement, and the domicile presence of major players in the region driving the growth and responsible for the dominance of the region. The well-established biotechnology, nanotechnology, and pharmaceutical industry coupled with rising awareness regarding advanced technologies for treatment of genetic and chronic diseases among the population in this region are also some of the key factors ensuring the dominance of the countries of this region.
Competitive Landscape
The gene delivery systems market is highly competitive and consists of a few major players. In terms of market share, few of the major players are currently dominating the market. And some prominent players are vigorously making collaborations, acquisition, and launching new products with the other companies to consolidate their market positions across the globe. Some of the companies which are currently dominating the market are Pfizer Inc., Novartis International AG, F. Hoffmann-La Roche AG, Becton, Dickinson and Company, and Uniqure N.V.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Chronic Diseases and Lifestyle Disorders
4.2.2 Technological Advancements in Research by Biopharmaceutical Companies
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.3.2 Reimbursement Issues
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Delivery Systems
5.1.1 Viral Gene Delivery Systems
5.1.1.1 Adenovirus Systems
5.1.1.2 Lentiviral Systems
5.1.1.3 Retroviral Systems
5.1.1.4 Others
5.1.2 Non Viral Gene Delivery
5.1.3 Combined Hybrid Delivery Systems
5.2 By Application
5.2.1 Oncology
5.2.2 Infectious Diseases
5.2.3 Cardiovascular Disorders
5.2.4 Diabetes
5.2.5 Pulmonary Disorders
5.2.6 Others
5.3 By Route of Administration
5.3.1 Oral
5.3.2 Injectable
5.3.3 Nasal
5.3.4 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer, Inc.
6.1.2 Novartis International AG
6.1.3 F. Hoffmann-La Roche AG
6.1.4 Becton, Dickinson and Company
6.1.5 Uniqure N.V.
6.1.6 Shenzhen SiBiono GeneTech Co.,Ltd
6.1.7 Bayer AG
6.1.8 Amgen Inc.
6.1.9 Shanghai Sunway Biotech Co., Ltd,
7 MARKET OPPORTUNITIES AND FUTURE TRENDS